Voraxaze Or Megludase Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The voraxaze or megludase market research report is one of a series of new reports that provides voraxaze or megludase market statistics, including the voraxaze or megludase industry's global market size, regional shares, competitors with a Voraxaze or Megludase market share, detailed voraxaze or megludase market segments, market trends and opportunities, and any further data you may need to thrive in the voraxaze or megludase industry. This voraxaze or megludase market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The growth in the forecast period can be attributed to rising prevalence of chronic diseases, growing number of drug approvals by regulatory bodies, ongoing research and development using methotrexate drugs, growing autoimmune disease cases, and growing geriatric population. Major trends in the forecast period include rising adoption of personalized medicine, increasing focus on early intervention strategies for high-risk patients, introduction of advanced delivery systems, emergence of digital health solutions, and advancements in diagnostic technologies.

The growing prevalence of cancer is expected to accelerate the growth of the voraxaze (megludase) market in the future. Cancer, a group of diseases marked by the uncontrolled growth and spread of abnormal cells, is becoming more common due to factors such as aging populations, lifestyle changes, environmental exposures, and better detection methods. Voraxaze is used to treat high methotrexate toxicity in cancer patients, which helps reduce severe side effects during chemotherapy. For example, the American Cancer Society projects that in 2024, the number of cancer cases in the U.S. will reach 2,001,140, up from 1,958,310 in 2023, a growth of 2.19%. As cancer rates increase, the demand for voraxaze is growing.

The rise in clinical trials is another factor expected to drive the voraxaze market forward. Clinical trials, which are research studies involving human participants to evaluate the safety and effectiveness of medical interventions, are increasing in number due to the demand for new treatments, advances in medical research, and the need to address emerging health challenges. Clinical trials help demonstrate Voraxaze’s safety and efficacy in reducing methotrexate toxicity, supporting regulatory approvals and boosting its use in medical practice. According to the National Institutes of Health, in 2023, around 479,000 clinical trials were registered in the U.S., marking an increase of approximately 9.5% from 2022. This rise in clinical trials is contributing to the growth of the voraxaze market.

The expansion of oncology care centers is also fueling the growth of the voraxaze market. Oncology care centers specialize in diagnosing, treating, and managing cancer, providing services such as chemotherapy, radiation, and surgery. The increasing incidence of cancer and the growing need for specialized cancer treatment and care are driving the expansion of these centers. More oncology care centers mean increased access to specialized treatments for methotrexate toxicity, which enhances the availability and adoption of Voraxaze among cancer patients undergoing chemotherapy. For instance, in 2023, the National Institutes of Health reported that there were 72 National Cancer Institute (NCI)-Designated Cancer Centers across the U.S., an increase of six from the previous year. This expansion is supporting the growth of the voraxaze market.

The key players in the voraxaze or megludase market are BTG Specialty Pharmaceuticals, SERB Pharmaceuticals.

North America was the largest region in the voraxaze or megludase market in 2024. The regions covered in voraxaze or megludase report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the voraxaze or megludase market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Voraxaze (glucarpidase) is a recombinant enzyme that helps reduce toxic methotrexate levels in patients with delayed clearance due to kidney dysfunction. It works by breaking down methotrexate into inactive metabolites, which can then be eliminated through non-renal pathways. Voraxaze plays a crucial role in managing severe methotrexate toxicity and preventing associated complications.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary indications for voraxaze include toxic plasma methotrexate levels, acute renal failure, and chemotherapy toxicity. Toxic plasma methotrexate refers to a condition in which there is an excessive concentration of methotrexate, a chemotherapy drug, in the bloodstream, potentially leading to severe toxicity. Voraxaze is distributed through various channels such as hospitals, specialty pharmacies, retail pharmacies, and online pharmacies, and is used by a wide range of end users, including adults, pediatric patients, and the geriatric population.

The voraxaze or megludase market consists of sales of glucarpidase enzyme products and supportive care products for chemotherapy. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.